Pineridge Advisors’s Core Laboratories CLB Stock Holding History

Pineridge Advisors’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-96	Closed	-$1.7K	–	652
2023 Q4	$1.7K	Buy	+96	New	+$1.93K	﹤0.01%	643

Other funds holding CLB

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Pineridge Advisors's CLB Position: Q1 2024 in Review

Pineridge Advisors sold out of Core Laboratories (CLB) in Q1 2024, closing a stake of 96 shares — an estimated $1.7K sold.

Pineridge Advisors first reported a position in CLB in Q4 2023 and held it in 1 quarter. The position peaked at $1.7K in Q4 2023. 197 funds tracked by Wall St. Rank hold CLB as of Q1 2024.

Pineridge Advisors reported no remaining Core Laboratories position as of Q1 2024 after selling out during the quarter.
Pineridge Advisors sold 96 Core Laboratories shares in Q1 2024, an estimated $1.7K.
Pineridge Advisors first reported a position in Core Laboratories in Q4 2023 and held it in 1 quarter.
Pineridge Advisors's Core Laboratories position peaked at $1.7K in Q4 2023.
197 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2024.

Based on Pineridge Advisors's 13F filing for Q1 2024, filed 16 May 2024.